(Source: Imperial Innovations Group plc) Posted on July 2, 2013 in Portfolio Progress Autifony in £2.75m collaboration with Universities of Manchester and Newcastle to progress a first-in-class drug for schizophrenia Imperial Innovations Group plc (AIM: IVO, 'Innovations', or 'the Group') a leading technology commercialisation and investment company, announces that its portfolio company, Autifony Therapeutics ('Autifony') is collaborating with leading research groups at the University of...
↧